|  |  |
| --- | --- |
| **Parallel EMA/EUnetHTA 21 Joint Scientific Consultation (JSC)**EUnetHTA 21 JSC Secretariat: EUnetHTA21-JSC@g-ba.de | **Date:** Click to select date |

|  |
| --- |
| Parallel EMA/EUnetHTA 21 Joint Scientific Consultation (JSC)**Application Form** **EUnetHTA 21 2nd Open Call (6 June, 2022 to 31 August, 2022)** |

**Please fill in all the predefined fields as accurately as possible.**

|  |  |
| --- | --- |
| **Unique Product Identifier** |  |
| **Substance** |
| * **INN** (if available)
 |   |
| * **Trade name** (if available)
 |   |
| * **Company product code**
 |   |
| **Description of the product & mechanism of the action** |    |
| **Type of product** | [ ]  Chemical [ ]  Generic [ ]  Antisense [ ]  NCE [ ]  Others[ ]  Bio(techno)logical [ ]  Classical biological: [ ]  Blood derived [ ]  Vaccine [ ]  Enzyme [ ]  Other biologicals [ ]  Recombinant DNA derived product: [ ]  Cytokine [ ]  Hormone [ ]  Monoclonal antibody [ ]  Vaccine [ ]  Transgene derived (animal/biopharm) [ ]  Other Recombinant [ ]  Similar biological [ ]  Nucleic acid-Based [ ]  DNA vaccine [ ]  Oncolytic virus[ ]  Advanced Therapy Medicinal Product (ATMP): [ ]  Gene therapy: [ ]  Autologous [ ]  Allogenic [ ]  Xenogenic [ ]  Somatic cell therapy: [ ]  Autologous [ ]  Allogenic [ ]  Xenogenic [ ]  Tissue-engineered product  [ ]  Autologous [ ]  Allogenic [ ]  Xenogenic[ ]  Therapeutic, scientific, or technical Innovation |
| **Is the product used together with a digital application?**  | [ ]  YES [ ]  NO If yes, please describe:  |
| **Is the product used together with a medical device or an *in vitro* diagnostic medical device?** | [ ]  YES [ ]  NO If yes, please describe:  |

Comments:

|  |  |
| --- | --- |
| **Intended indication for the scope of the current JSC** |   |
| **Products with market authorization in similar indication** |   |
| **Products in development with similar indication** |   |
| **Application type EMA (anticipated):** | [ ]  Initial market application (IMA)[ ]  Extension of Indication (EoI)[ ]  Line Extension (LE)[ ]  First in class (FC)[ ]  Priority Medicine (PRIME)[ ]  Accelerated access (AC)[ ]  Orphan designation (OD)if current OD, please provide: OD number: EU/ Date: YYYY-MM-DD Indication for which OD has been granted:  |
| **Therapeutic field**  | [ ]  Cancer [ ]  HIV/AIDS [ ]  Diabetes[ ]  Neurodegenerative disorder [ ]  Viral disease[ ]  Autoimmune disease/dysfunction[ ]  Cardiovascular [ ]  Other |
| **ATC code** (broad or detailed if known) | Click to select. or detail here:  |

Comments**:**

|  |  |
| --- | --- |
| **Applicant** | **Company Name:** **Address:** **Country:**   |
| **Contact Person details** | **Title and Name:** **Direct Tel:** **Fax:** **Email:**  |
| **Alternate Contact Person details[[1]](#endnote-1)** | **Title and Name:** **Direct Tel:** **Fax:** **Email:**  |

Comments:

|  |  |
| --- | --- |
| **Small and Medium Sized Enterprises (SME)** | [ ]  NO – N/A |
| [ ]  YES |
|  - SME Number:  |

|  |  |
| --- | --- |
| **Consultant on behalf of Applicant** (if applicable) | Title and Name: Direct Tel: Fax: Email:  |
| **Contact Person details** | Title and Name: Direct Tel: Fax: Email:  |
| **Alternate Contact Person details** (if applicable) | Title and Name: Direct Tel: Fax: Email:  |
| **Letter of authorisation from applicant** | [ ]  NO (to be provided within 15 days)[ ]  YES (please attach) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Aimed date of the draft Briefing Package ready for submission and deadline to receive final EUnetHTA 21 recommendations**(*please refer to the EUnetHTA 21 Joint Scientific Consultation procedure for the full timeline*) |

|  |  |  |
| --- | --- | --- |
| Please select (multiple choices possible) | Draft Briefing Package submission | EUnetHTA 21 Final Written Recommendation |
|[ ]  24 Oct 2022 | 8 Mar 2023 |
|[ ]  5 Dec 2022 | 12 Apr 2023 |
|[ ]  9 Jan 2023 | 10 May 2023 |
|[ ]  13 Feb 2023 | 7 Jun 2023 |
|[ ]  13 Mar 2023 | 5 Jul 2023 |

 |

Comments:

|  |  |
| --- | --- |
| **Clinical trial phase(s) for which JSC is requested** | [ ]  Phase I [ ]  Phase II [ ]  Phase III[ ]  Phase IV, PLEG (only in conjunction with request for discussion of pivotal trial design)If the clinical trial phase for which JSC is requested is not Phase III: Is a Phase III study planned: [ ]  YES [ ]  NOIf no, please explain why not:  |
| **Are the trial(s) for which advice is requested on-going?** | [ ]  YES [ ]  NOIf yes, please specify study registry/ID number:

|  |  |
| --- | --- |
| Study title | registry/ID-number |
|   |   |
|   |   |
|   |   |

 |
| **Does the product target an unmet need?** | [ ]  YES [ ]  NOIf yes, please describe:  |
| **Is the product the first in its class?** | [ ]  YES [ ]  NOIf yes, please describe:  |
| **Does the product have potential impact on patients, public health, or healthcare systems?** | [ ]  YES [ ]  NOIf yes, please describe:  |
| **Will the product have significant cross-border dimension?** | [ ]  YES [ ]  NOIf yes, please describe:  |
| **Will the product have a major Union-wide added value?** | [ ]  YES [ ]  NOIf yes, please describe:  |
| **Does the product address Union clinical research priorities?**  | [ ]  YES [ ]  NOIf yes, please describe:  |
| **Summary of expected information (study phase, minimum information on PICO scheme) annexed[[2]](#endnote-2)** | [ ]  YES [ ]  NO |

Comments:

|  |  |
| --- | --- |
| **Other scientific advice (received or planned)** | EMA Scientific Advice: [ ]  NO [ ]  YES Date: Click to select datePrevious EUnetHTA Early Dialogue (ED)[ ]  NO [ ]  YES, ED-Number: Date: Click to select dateOther scientific advices with individual HTA bodies:  [ ]  NO / Not planned [ ]  YESWhich countries:  |

Comments:

|  |  |
| --- | --- |
| **Status of the product / pipeline** | [ ]  MA granted in another indication[ ]  MA not yet granted[ ]  N/A |
| **Marketing Authorisation (MA) already granted in another indication** | Date of MA granting: Route of MA: [ ]  National Procedure[ ]  MRP/Decentralised Procedure[ ]  Centralised ProcedureSpecify in which indication:  |
| **MA not yet granted** | MA Application planned date: Route of MA planned: [ ]  National Procedure[ ]  MRP/Decentralised Procedure[ ]  Centralised Procedure (according to Reg. (EC) No 726/2004) |

Comments:

|  |  |
| --- | --- |
| **Area of Advice** | Please briefly outline the scope/content of each question, for each area of advice following topic order proposed below:[ ]  Target Population: [ ]  Intervention: [ ]  Comparator choice: [ ]  Outcomes choice: [ ]  Study Design including statistical analysis method: [ ]  Post-Launch Evidence Generation (only in conjunction with request for discussion of pivotal trial design) [ ]  Health Economics:  |

Comments:

**Important application submission instructions:**

1. Please send this form in Word format. Do not convert it into PDF.
2. The Application Form for parallel EMA/EUnetHTA 21 JSC should be submitted to the EUnetHTA 21 JSC Secretariat via Eudralink (EUnetHTA21-JSC@g-ba.de).
1. An additional alternate contact person is requested in case the main contact point is unavailable. All official correspondence will be sent to both contact persons. If a consultant is acting on behalf of the applicant, the alternate contact person details are not requested. [↑](#endnote-ref-1)
2. As available, a summary of expected information (study phase, high level design with minimum information on Population, Intervention, Comparator, Outcomes (PICO)) for the intended product and indication must be annexed when submitting the Application Form. [↑](#endnote-ref-2)